Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CKD Bio Corp. (063160.KS)
Seoul, KR
CKD Bio Corp., a South Korean company founded in 1941 and headquartered in Seoul, specializes in the production and distribution of pharmaceutical active ingredients (APIs). Their manufacturing processes leverage diverse technologies, including fermentation, chemical synthesis, and biotechnology. The company's extensive portfolio of APIs targets a broad spectrum of therapeutic applications, encompassing antibiotics, beta-lactamase inhibitors, immunosuppressants, oncology treatments, anti-obesity medications, dry eye remedies, antiviral and antituberculosis agents, antihyperlipidemics, and probiotics. Beyond its core manufacturing, CKD Bio Corp. also provides contract research, development, and manufacturing (CRDMO) services for APIs, pharmaceutical intermediates, and probiotic formulations. The company actively exports its products, establishing a global reach.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.91% | -7.12% | -13.12% | -19.67% | -20.24% | -16.71% | -25.17% | -36.28% | -71.12% | -38.63% | -15.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-6.8% Q1'26: -4.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-133.2% Q1'26: -325.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-7.2% Q1'26: -6.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.3% Q1'26: -4.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.3% Q1'26: -2.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×7.53× Q1'26: -21.63× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
106.69B
est: 1.22T (-91.2%)
|
113.01B
est: 114.90B (-1.6%)
|
118.19B
est: 124.90B (-5.4%)
|
124.51B
est: 135.90B (-8.4%)
|
137.18B
est: 134.75B (+1.8%)
|
124.60B
est: 158.50B (-21.4%)
|
142.24B
est: 175.20B (-18.8%)
|
156.04B
est: 175.70B (-11.2%)
|
160.35B
est: 167.30B (-4.2%)
|
171.76B
est: 174.40B (-1.5%)
|
| EBITDA |
19.18B
est: 93.47B (-79.5%)
|
21.26B
est: 8.84B (+140.6%)
|
18.87B
est: 9.61B (+96.4%)
|
15.96B
est: 10.45B (+52.8%)
|
25.57B
est: 10.36B (+146.7%)
|
19.87B
est: 12.19B (+63.0%)
|
5.56B
est: 13.47B (-58.7%)
|
2.29B
est: 13.51B (-83.1%)
|
-1.63B
est: 12.87B (-112.7%)
|
31.17B
est: 46.39B (-32.8%)
|
| EBIT |
8.28B
est: -37.52B (+122.1%)
|
12.27B
est: -3.55B (+445.8%)
|
9.80B
est: -3.86B (+354.1%)
|
9.42B
est: -4.20B (+324.6%)
|
15.79B
est: -4.16B (+479.6%)
|
7.69B
est: -4.89B (+257.1%)
|
-11.42B
est: -5.41B (-111.2%)
|
-15.65B
est: -5.42B (-188.5%)
|
-19.21B
est: -5.17B (-271.9%)
|
14.48B
est: 33.69B (-57.0%)
|
| Net Income |
6.65B
est: 8.30B (-19.8%)
|
9.43B
est: 10.23B (-7.8%)
|
8.02B
est: 11.90B (-32.6%)
|
7.96B
est: 13.33B (-40.3%)
|
12.26B
est: 12.85B (-4.5%)
|
6.21B
est: 17.14B (-63.8%)
|
-6.58B
est: 21.27B (-130.9%)
|
-16.70B
est: -7.69B (-117.3%)
|
-24.19B
est: -3.85B (-528.2%)
|
8.70B
est: -329.34M (+2,741.9%)
|
| SGA |
4.47B
est: 64.85B (-93.1%)
|
5.00B
est: 6.13B (-18.4%)
|
4.86B
est: 6.66B (-27.1%)
|
3.73B
est: 7.25B (-48.6%)
|
5.27B
est: 7.19B (-26.7%)
|
6.15B
est: 8.46B (-27.3%)
|
6.94B
est: 9.35B (-25.7%)
|
9.14B
est: 9.37B (-2.5%)
|
12.51B
est: 8.93B (+40.2%)
|
5.50B
est: 11.75B (-53.2%)
|
| EPS |
1,297.00
est: 1,512.38 (-14.2%)
|
1,839.00
est: 1,864.76 (-1.4%)
|
1,563.00
est: 2,169.52 (-28.0%)
|
1,477.21
est: 2,429.52 (-39.2%)
|
2,391.06
est: 2,341.93 (+2.1%)
|
1,147.30
est: 3,125.00 (-63.3%)
|
-1,198.81
est: 3,877.00 (-130.9%)
|
-3,044.61
est: -1,401.00 (-117.3%)
|
-4,409.90
est: -702.00 (-528.2%)
|
1,586.02
est: -60.00 (+2,743.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 24.9K | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Yil Kang | Vice President & Director | — | male |
| Wan-Kap Park | Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 063160.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
